Effect of Fosamax on Remodeling of the Bone Tissue and Bone Mass in Postmenopausal and Senile Osteoporosis

S. S. Rodionova , A. F. Kolondaev , M. A. Makarov , N. V. Burdigina

N.N. Priorov Journal of Traumatology and Orthopedics ›› 1998, Vol. 5 ›› Issue (3) : 29 -33.

PDF
N.N. Priorov Journal of Traumatology and Orthopedics ›› 1998, Vol. 5 ›› Issue (3) : 29 -33. DOI: 10.17816/vto104561
Articles
research-article

Effect of Fosamax on Remodeling of the Bone Tissue and Bone Mass in Postmenopausal and Senile Osteoporosis

Author information +
History +
PDF

Abstract

In 11 patients with postmenopausal and senile osteoporosis and decreased remodeling the effect of Fosamax on the bone tissue mass in different segments of skeleton was studied. Course of treatment was 12 months. Fosamax 10 mg/daily was found to provide marked analgesic effect to improve clinical course of disease during the first 6 months of treatment. Using dual-energy-x-ray absorptiometry the increase of bone tissue mass was detected in all examined skeleton segments (by 3.7-8.5%) of patients with initial low resorption (low oxyprolinuria and calcinuria). It mainly testified the stimulate effect of Fosamax on the process of bone formation. Increase of bone mass in femur neck confirmed that Fosamax unlike other medicines influenced not only the trabecular bone but the cortical one as well.

Keywords

Fosamax / osteoporosis / bone mass / remodeling / oxyproline

Cite this article

Download citation ▾
S. S. Rodionova, A. F. Kolondaev, M. A. Makarov, N. V. Burdigina. Effect of Fosamax on Remodeling of the Bone Tissue and Bone Mass in Postmenopausal and Senile Osteoporosis. N.N. Priorov Journal of Traumatology and Orthopedics, 1998, 5(3): 29-33 DOI:10.17816/vto104561

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Пат. РФ 2029550. Способ регуляции метаболизма костной ткани / Родионова С.С., Швец В.Н., Машковская Т.А. //Бюл. Изобрет. — 1995. — N 6.

[2]

Родионова С.С., Зацепин С.Т., Швец В.Н., Машковская Т.А. //Новый хелатирующий агент ксидифон в фармакологической токсикологии и терапии. — М., 1990. — С. 18-21.

[3]

Швец В.Н., Панкова А.С., Голъдовская М.Д. и др. //Косм. биол. — 1988. — N 4. — С. 45-55.

[4]

Adami S., Passeri М., Ortolani S. et al. //Osteoporosis Int. — 1993. — Vol. 3. — P. 211-227.

[5]

Balena R. et al. //J. Clin. Invest. — 1993. — Vol. 92. — P. 2577-2586.

[6]

Chesnut C.H., Harris S.T. //Osteoporosis Int. — 1993. — Vol. 3, Sup. 3. — P. 517-519.

[7]

Cooper C., Campion G. //Ibid. — 1992. — Vol. 2. — P. 258-259.

[8]

Cummings S.P., Black D.M., Vogt T.M. //J. Bone Min. Res. — 1996. — Vol. 11, Sup. 1. — P. 29.

[9]

Devogelaer J.P., Broil H., Correa-Rotter R., Cumming D.C. et al. //Bone. — 1996. — Vol. 18, N 2. — P. 141-150.

[10]

Faulkner K.G., McClung M., Cummings S.R. //J. Bone Miner. Res. — 1994. — Vol. 9. — P. 1065-1070.

[11]

Fleish H. //Osteoporosis: Symposium on Osteoporosis and Consensus Development Conference, 4th. — Hong Kong. — 1993. — P. 134-136.

[12]

Marcus R., Black D., Genant H.K., Cummings S.R. //J. Bone Min. Res. — 1996. — Vol. 11, Sup. 1. — P. m637.

[13]

Mazess R. //Calcif. Tiss. Int. — 1990. — Vol. 47. — P. 191-193.

[14]

Mikhail M.B., Vaswani A.N., Aloia J.P. //Osteoporosis Int. — 1996. — Vol. 6. — P. 22-24.

[15]

Raisz L., Kream B. //New Engl. J. Med. — 1981. — Vol. 309. — P. 83-89.

RIGHTS & PERMISSIONS

Eco-Vector

AI Summary AI Mindmap
PDF

109

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/